Merck’s Gardasil Is Promising, Study Says
From Reuters
An experimental vaccine from Merck & Co. has proved highly effective at stopping the virus associated with most cases of cervical cancer and genital warts, scientists said.
Gardasil, which could reach the market in 2006, is designed to protect women against four strains of the human papillomavirus. It is competing against GlaxoSmithKline’s Cervarix, which targets the two strains responsible for cervical cancer.
